MindMedMNMD
About: Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
Employees: 57
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
79% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 28
79% more call options, than puts
Call options by funds: $4.76M | Put options by funds: $2.67M
43% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 21
3% more funds holding
Funds holding: 150 [Q2] → 155 (+5) [Q3]
2.8% more ownership
Funds ownership: 58.07% [Q2] → 60.87% (+2.8%) [Q3]
6% less capital invested
Capital invested by funds: $301M [Q2] → $282M (-$18.9M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Patrick Trucchio 42% 1-year accuracy 74 / 175 met price target | 513%upside $55 | Buy Reiterated | 31 Jan 2025 |
Evercore ISI Group Gavin Clark-Gartner 36% 1-year accuracy 4 / 11 met price target | 156%upside $23 | Outperform Initiated | 28 Jan 2025 |
Chardan Capital Rudy Li 50% 1-year accuracy 2 / 4 met price target | 123%upside $20 | Buy Initiated | 20 Dec 2024 |
Oppenheimer Francois Brisebois 51% 1-year accuracy 19 / 37 met price target | 123%upside $20 | Outperform Reiterated | 17 Dec 2024 |
Financial journalist opinion









